AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.

from Health and Science https://ift.tt/xpPEcNM
https://ift.tt/PGF1R6K
https://ift.tt/60Ruvdw